...

IEDAT Intra Erythrocyte Dexamethasone in the treatment of Ataxia Telangiectasia

The ATTEST trial will involve more than 20 centers worldwide and should allow to collect relevant safety and efficacy data for regulatory filing to obtain market authorization in the EU and the USA by 2019.

As part of the IEDAT project, additional scientific activities along with ATTEST will be conducted.

The Ataxia Telangiectasia Society will be in charge of the register design and development.

b) A neurological scale specific for AT (AT-NEST) will be developed and tested under the responsibility of Johns Hopkins University.

c) Under the responsibility of the University of Urbino, investigations on the mechanisms of action of the EDS will be conducted with the objective to provide supportive data to the validation of a possible biomarker predictive of treatment efficacy.

d) The ATTEST phase III trial, conducted under the responsibility of EryDel, is an international, multi-center, 1 year, randomized, prospective, double-blind, placebo-controlled, designed to assess the effect of 2 dose ranges of EDS, administered monthly by IV infusion, on neurological symptoms of AT patients.

partners / contact

EryDel S.p.A.

Italy

Antonio Ferrari

Antonio Ferrari

Antonio Ferrari, MD, PhD, MBA Global Medical Director Head of Global Clinical Development EryDel s.p.a.

JOHNS HOPKINS UNIVERSITY

United States

Jenny Wright

Jenny Wright

MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER

Israel

Andreea Nissenkorn

Andreea Nissenkorn

Pediatric Neurologist Head of Service for Rare Disorders Pediatric Neurology Unit Safra Children Hospital , Sheba Med

JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN

Germany

Stefan Zielen

Stefan Zielen

Universita' degli Studi di Urbino Carlo Bo

Italy

Mauro Magnani

Mauro Magnani

THE ATAXIATELANGIECTASIA SOCIETY

United Kingdom

William Davis

William Davis

ABSISKEY CP

France

Olivier Guerard

Olivier Guerard

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667946 . This publication [communication] reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

graph - chart

Start 01/01/2016
60% 20/11/2017
End 30/04/2019
Budget allocation . M€ Budget allocation
Effort 322 p*m Effort
Effort 8 persons Full time equivalent

news

IEDAT General Assembly 2017

2017-10-13

The IEDAT consortium will meet in Stansted (London) next October, for the second General Assembly, an important step for the project, which ...

View more

Investigator Meeting

2016-01-12

January, 2016 - Investigator meeting of the IEDAT H2020 project organised by Erydel.

View more

EryDel Consortium Gains €6 million of EU Funding

2016-01-07

EU Funding for development of EDS for the treatment of Ataxia Telangiectasia (AT).On behalf of the IEDAT Consortium, EryDel SpA announc...

View more

events

2017-10-13

Second General Assembly IEDAT

2016-11-14

First General Assembly

2016-02-22

IEDAT - Kick Off Meeting

documents

contact us

project netboard login

project netboard login